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ABSTRACT
Objective: To create and validate a frailty assessment
tool for community-dwelling adults aged ≥75 years.
Design: Longitudinal, population-based study.
Setting: The Survey of Health, Ageing and Retirement
in Europe (SHARE).
Participants: 4001 women and 3057 men aged
≥75 years from the second wave of SHARE. 3325
women and 2587 men had complete information for the
frailty indicators: fatigue, low appetite, weakness,
observed gait (walking without help, walking with help,
chairbound/bedbound, unobserved) and low physical
activity.
Main outcome measures: The internal validity of the
frailty indicators was tested with latent class analysis, by
modelling an underlying variable with three ordered
categories. The predictive validity of the frailty
classification was tested against 2-year mortality and 4-
year disability. The mortality prediction of SHARE-FI75+
was compared with that of previously operationalised
frailty scales in SHARE (SHARE-FI, 70-item index,
phenotype, FRAIL).
Results: In both genders, all frailty indicators
significantly aggregated into a three-category ordinal
latent variable. After adjusting for baseline age,
comorbidity and basic activities of daily living (BADL)
disability, the frail had an OR for 2-year mortality of
2.2 (95% CI 1.2 to 3.8) in women and 4.2 (2.6 to 6.8)
in men. The mortality prediction of SHARE-FI75+ was
similar to that of the other SHARE frailty scales. By
wave 4, 49% of frail women (78 of 159) had at least
one more limitation with BADL (compared with 18%
of non-frail, 125 of 684; p<0.001); in men, these
proportions were 39% (26 of 66) and 18% (110 of
621), respectively (p<0.001). A calculator is supplied
for point-of-care use, which automatically replicates
the frailty classification for any given measurements.
Conclusions: SHARE-FI75+ could help frailty case
finding in primary care and provide a focus for
personalised community interventions. Further
validation in trials and clinical programmes is needed.
INTRODUCTION
Frailty is “a state of vulnerability to poor reso-
lution of homoeostasis after a stressor event
and is a consequence of cumulative decline in
many physiological systems during a lifetime.”1
Campbell and Buchner2 deﬁned frailty as
“a condition or syndrome which results from a
multi-system reduction in reserve capacity to
the extent that a number of physiological
systems are close to, or past, the threshold of
symptomatic clinical failure; and as a conse-
quence the frail person is at increased risk of
disability and death from minor external stres-
ses.” A systematic review of the literature
including studies from the UK, the USA,
Europe, Australia and Canada estimated that
in community-dwelling adults aged 65
and older, the overall prevalence of frailty is
Strengths and limitations of this study
▪ The systematic identification of frailty in people
above the age of 75 in primary care is currently
on the health policy agenda.
▪ This study was carried out to create and validate
a frailty assessment tool that could be easy to
implement in primary care practice.
▪ The Survey of Health, Ageing and Retirement in
Europe (SHARE)-FI75+ was validated as an
age-independent marker of risk for mortality and
incident disability.
▪ An open access calculator is supplied that auto-
matically classifies a participant as non-frail, pref-
rail or frail given any indicator measurements.
▪ A future clinical validation of SHARE-FI75+ may
enable primary care implementation of frailty
case finding with solely self-reported and obser-
vational markers not requiring additional equip-
ment or techniques.
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10.7% (95% CI 10.5% to 10.9%); that prevalence increases
with age and is higher in women.3
In Europe, by 2060 those aged 65+ will comprise 30% of
the population, and one person in eight will be aged 80 or
more.4 In England, around 15% of the population were
aged ≥65 years in 2008, and this is expected to increase to
nearly 25% during the next two decades, with the fastest
growing sector of the population being people aged
>75 years.5 Even so, the association between age and
health status is highly variable in the older population:6 on
the one hand, many community-dwelling older people are
in good physical and cognitive health, and often present
to primary care practitioners with relatively well-deﬁned
problems that can be managed by single interventions
and/or organ-speciﬁc specialist referral.
On the other hand, other older patients present with
less well-deﬁned problems such as subacute functional
decline.7 These patients may be complex because their
presentation can be rooted in multiple factors, including
morbidity (eg, physical, cognitive), polypharmacy, psy-
chosocial inﬂuences and social vulnerability, in varying
degrees and combinations. In primary care, where con-
sultation times and access to multidisciplinary assess-
ments are limited, unravelling that complexity for the
ﬁrst time can prove challenging. This is why these more
complex patients often need a comprehensive geriatric
assessment (CGA).7 8
CGA is deﬁned as a multidisciplinary diagnostic and
intervention process that identiﬁes physical, cognitive,
environmental, psychosocial and socioeconomic compo-
nents that inﬂuence an older adult’s health. CGA is based
on the premise that a systematic and personalised evalu-
ation may identify remediable problems and, by tackling
them in a coordinated and holistic manner, the risk of
adverse outcomes for the person will be minimised.9
CGA can provide important positive impacts on the
health of older people, including more thorough diag-
noses, improved overall function and reduced premature
mortality.10–14 These beneﬁts have costs: reﬂecting its
usual interdisciplinary composition, and the time it
takes to gather the relevant data, CGA is labour-intensive
and not inexpensive. Therefore, from the point of view
of both referrers and providers of CGA, it is important
to identify those who need it the most, in order to
promote equitable access to this important (but ﬁnite)
expert multidisciplinary resource.
Although no standard criteria have been validated to
readily identify patients who are likely to beneﬁt from
CGA,9 chronological age alone is unlikely to be an
effective criterion given the biological heterogeneity of
the population of older people.6 It has been argued that
the concept of frailty, which is an age-independent
marker of risk for adverse outcomes, may ﬁt the biopsy-
chosocial model of primary care and provide care com-
missioners with a focus for targeting resources at an
ageing population;15 16 in addition, it may help avoid
age discrimination in the provision of health and social
care services for older people.17
In 2012, a workshop of the International Association of
Gerontology and Geriatrics, the WHO and the French
Society of Geriatrics and Gerontology concluded that
one of the research priorities for the coming years
should be to develop an assessment tool for frailty that
can be administered quickly and easily by general practi-
tioners, nurses, pharmacists, home health providers,
social workers and other healthcare workers, whereby a
positive screen would indicate the need for GCA and
design of tailored interventions.18 In 2013, a draft report
for the UK National Screening Committee concluded
that at present there is insufﬁcient evidence to support
the implementation of systematic screening in old age to
prevent hospitalisation and/or early death; however, the
report also highlighted areas for further research includ-
ing the identiﬁcation of measurement tools (including
frailty assessment tools) which are the best predictors of
adverse outcomes in community-dwelling older people.19
This echoes calls from clinicians to develop more efﬁ-
cient methods to detect frailty and measure its severity in
routine clinical practice, especially in primary care.1
Indeed, family physicians need easy-to-use instruments
for frailty.20
As such, in order to develop instruments for assessing
frailty, it is important to clearly identify the deﬁnition of
frailty and perhaps its subtypes. In its recent draft guid-
ance, the UK National Institute for Health and Care
Excellence (NICE) broadly refers to frailty as a situation
of high risk of health problems including disability and
mortality.21 Building around the idea of frailty as an
age-independent marker of risk, many deﬁnitions of
frailty have been proposed over the years, ranging from
narrow deﬁnitions involving purely physical aspects (ie,
physical phenotype) to much broader deﬁnitions which,
in addition to physical factors (eg, physical signs,
comorbidities, disabilities), also include cognitive and
psychosocial aspects.3 22 The frailty index based on CGA
is an example of the latter approach.23 24 It is increasingly
recognised that rather than being competitive or mutu-
ally exclusive, different approaches are complementary
and suitable for different purposes or scenarios.25
According to the physical phenotype approach, frailty
is identiﬁed when three or more of the following criteria
are present: unintentional weight loss, self-reported exhaus-
tion, weakness (by assessing handgrip strength), slow
walking speed and low physical activity.26 This approach
deﬁnes two additional states: prefrail (ie, one or two cri-
teria present) and non-frail (ie, none of the criteria
present). According to the biological theory underpin-
ning the frailty phenotype, comorbidity is a risk factor
for frailty, and frailty is a precursor of disability.27 28 An
internal validation of the frailty phenotype using latent
class analysis (LCA) showed that the ﬁve criteria aggre-
gated statistically into a syndrome.29 The phenotype was
found to be valid against incident disease, hospitalisa-
tion, falls, disability and mortality, all independently of
chronological age.26 The potential usefulness of Fried’s
phenotypic criteria for screening purposes was
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demonstrated in a randomised controlled trial that
assessed the effectiveness of CGA and subsequent inter-
vention in prefrail and frail community-dwelling older
people, ﬁnding a favourable outcome based on frailty
status and the Barthel Index of activities of daily living.30
A problem with Fried’s deﬁnition is that the dichoto-
misation of individual criteria that are measured on a
continuous scale (ie, handgrip strength, walking speed
and physical activity) needs to be done retrospectively
according to the lowest 20th centile rule, and there are
further stratiﬁcations. This requires the use of values
from a reference population, which may not be available
to primary care practitioners. Thus, frailty assessment
with the original Fried’s criteria is unlikely to be feasible
for point-of-care testing in primary care.
Since surrogates for individual frailty phenotype cri-
teria are possible,31 the Frailty Instrument for Primary
Care of the Survey of Health, Ageing and Retirement in
Europe (SHARE-FI)32 was developed to provide health-
care practitioners with a phenotypic frailty assessment
tool that does not require post hoc calculations and can
be scored immediately after an individual assessment,
with reference to a large population-based European
sample. SHARE-FI is based on a modiﬁed phenotypic
approach (fatigue, low appetite, weakness by handgrip
strength, difﬁculties walking or climbing stairs and low
physical activity) and is intended for community-
dwelling Europeans aged ≥50. SHARE-FI is fully non-
commercial and its web-based calculators (for each
gender) are freely accessible on BMC Geriatrics (http://
www.biomedcentral.com/1471-2318/10/57/additional)32
and on https://sites.google.com/a/tcd.ie/share-frailty-
instrument-calculators/.
The ﬁve SHARE-FI components have been shown
(through LCA) to have internal validity,32 33 and the
instrument has been validated against incident mortal-
ity34 35 and disability,36 independently of chronological
age. A consensus group consisting of delegates from six
major international, European and US societies referred
to SHARE-FI as an example of a well-validated frailty
model.37 In a systematic review, Pialoux et al38 compared
the properties of 10 frailty screening tools for primary
care, and identiﬁed SHARE-FI as potentially suitable. In
addition, a systematic review by the Oxford Centre for
Monitoring and Diagnosis in Primary Care concluded that
SHARE-FI may be a good screening instrument.39
Even though SHARE-FI has been piloted in clinical set-
tings such as a geriatric day hospital,40 an intermediate
care rehabilitation facility41 and acute hospitals,42 43 its use
in primary care may be less feasible, due to the fact that
handgrip strength is not routinely assessed in primary
care. In addition, given the considerable variation in
methods of assessing grip strength, which can affect the
values recorded,44 the exact SHARE (Survey of Health,
Ageing and Retirement in Europe) grip measurement
protocol45 needs to be observed for every SHARE-FI meas-
urement. This may be a disincentive for busy general prac-
titioners. In contrast, the detection of slow walking speed
has been proposed as an easier approach to the screening
of frailty in the primary care setting.46–50
In SHARE, those aged 75 years or more were offered
an assessment of their walk.51 The present study endea-
voured to apply the same methodology used for
SHARE-FI to create and validate a new frailty assessment
tool in SHARE intended for the 75+, based on walking
test information as opposed to handgrip strength. If
such an instrument had comparable validity (in terms of
mortality and disability prediction), it might be easier to
implement in primary care practice since it would not
require handgrip strength assessment.
METHODS
Participants
Participants were women and men aged 75 years or
more who were included in the second wave of SHARE
(release 2.6.0, as of 29 November 2013), corresponding
to nationally representative samples of 14 European
countries (Austria, Germany, Sweden, the Netherlands,
Spain, Italy, France, Denmark, Greece, Switzerland,
Belgium, Czechia, Poland and Ireland). Wave 2 was
chosen instead of wave 1 in order to maximise the 75+
sample size (Czechia, Poland and Ireland did not par-
ticipate in wave 1: http://www.share-project.org/home0/
overview.html, last accessed: 30 July 2014).52 Data for
wave 2 were collected between 2006 and 2007.
SHARE aimed at extracting, from each country, prob-
ability samples that would allow inferring from the sample
to the ﬁnite population of Europeans aged 50 and over.
The ofﬁcial target population was deﬁned as all individuals
born in 1954 or earlier, speaking the ofﬁcial language of
the country and not living abroad or in an institution
(such as a prison or institution for older people) during
the duration of the ﬁeldwork, and their spouses/partners
independently of age.53 For the total pooled sample in
wave 1 (N=31 115), country-speciﬁc individual response
rates ranged between 73.7% and 93.3%, with an average
of 85.3% (http://www.share-project.org/data-access-
documentation/sample.html, last accessed: 30 July 2014).
In wave 2, respondents from wave 1 were recontacted
and a refresher sample was also drawn for all ﬁrst wave
countries (except Austria and the Flemish part of
Belgium). For the refresher sample, the same sampling
methods were used as in wave 1; only cohorts born in
1955 and 1956 were oversampled to keep the sample rep-
resentative of the population 50 years old and older.54
For the prospective validation of SHARE-FI75+, we
used the subset of wave 2 participants for whom mortal-
ity data at wave 3 were available (wave 3 data were col-
lected in 2008–2009 for all countries except for Ireland:
2009–2010). In addition, we used wave 4 data55 56
(2011–2012) to validate the frailty instrument against
incident disability. Wave 4 mortality data will not be avail-
able until the release of wave 5 data (http://www.
share-project.org/home0/wave-5.html, last accessed: 23
August 2014).
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Frailty variables
The frailty criteria for SHARE-FI75+ were deﬁned as
follows:
▸ Fatigue was identiﬁed as a positive answer to the ques-
tion: “In the last month, have you had too little
energy to do the things you wanted to do?” A positive
answer (Yes) was recoded as 1, and No was recoded
as 0. This criterion is the same as in SHARE-FI.32
▸ The low appetite criterion was fulﬁlled by reporting a
“Diminution in desire for food” in response to the
question: “What has your appetite been like?” or, in
the case of a non-speciﬁc or uncodeable response to
this question, by responding ‘Less’ to the question:
“So, have you been eating more or less than usual?”
The presence of the criterion was coded as 1 and its
absence as 0. This criterion is the same as in
SHARE-FI.32
▸ Weakness was deﬁned as a positive answer to either of
the following two items: “Because of a health
problem, do you have difﬁculty (expected to last
more than 3 months) getting up from chair after
sitting for long periods?” or “…lifting or carrying
weights over 10 pounds/5 kilos, like a heavy bag of
groceries?” One or two positive answers received the
score of 1, and two negative answers received the
score of 0. The chair-rise question aims to capture
lower-body muscle weakness,57 and the one on lifting
or carrying weights aims to capture upper-body
muscle weakness.
▸ Slowness. In SHARE, only respondents who were
75 years or older were asked to complete a walking
test. As per the walking test protocol,58 59 the inter-
viewer was asked to record the respondent status
beforehand as follows:
– Observed walking without help of another person
or using support;
– Observed walking with help of another person or
using support;
– Not observed—in wheelchair;
– Not observed—bedbound;
– Not observed—uncertain if respondent has
impairment.
For coding the slowness variable, we deﬁned the fol-
lowing subvariables: ‘Observed gait1’, ‘Observed gait2’,
‘Observed gait3’ and ‘Observed gait4’. In the algorithm,
only one receives a value equal to 1, depending on the
‘respondent status’ recorded. All others receive a value
of 0. For example, selecting the ﬁrst option (‘without
help’) saw ‘Observed gait1’ coded as 1 and all others,
that is, ‘Observed gait2’, ‘Observed gait3’ and ‘Observed
gait4’, coded as 0. Similarly, selecting the second option
(‘with help’) saw ‘Observed gait2’ coded as 1 and all
others coded as 0. Selecting either the third or fourth
option (‘not observed—wheelchair or bedbound’) saw
‘Observed gait3’ coded as 1, and all others coded as 0.
Finally, selecting the ﬁfth option (‘not observed—uncer-
tain if impediment’) saw ‘Observed gait4’ coded as 1,
with all others coded as 0.
▸ The low physical activity criterion was assessed by the
question: “How often do you engage in activities that
require a low or moderate level of energy such as gar-
dening, cleaning the car, or taking a walk?”
Responses were coded as follows: 1=“More than once
a week”; 2=“Once a week”; 3=One to three times a
month” and 4=“Hardly ever or never”. This criterion
is the same as in SHARE-FI.32
Measures for cross-sectional correlations
Sociodemographic domain:
▸ Age (years). It was obtained by subtracting the year of
birth from 2007.
▸ No more than primary education: deﬁned as code 0 (pre-
primary education) or 1 (primary education or ﬁrst
stage of basic education) from the International
Standard Classiﬁcation of Education (ISCED, 1997
version).60
Physical domain:
▸ Poor self-rated health: deﬁned as the choice of ‘poor’
among the following options: ‘excellent’, ‘very good’,
‘good’, ‘fair’ and ‘poor’.
▸ Number of chronic diseases: calculated as the sum of
afﬁrmative self-reports to the following conditions (if
diagnosed by a doctor): (1) heart attack or myocardial
infarction or coronary thrombosis or any other heart
problem including congestive heart failure; (2) high
blood pressure or hypertension; (3) high blood choles-
terol; (4) stroke or cerebrovascular disease; (5) diabetes
or high blood sugar; (6) chronic lung disease such as
chronic bronchitis or emphysema; (7) asthma; (8) arth-
ritis, including osteoarthritis, or rheumatism; (9) osteo-
porosis; (10) cancer or malignant tumour, including
leukaemia or lymphoma, but excluding minor skin
cancers; (11) stomach or duodenal ulcer, or peptic
ulcer; (12) Parkinson’s disease; (13) cataracts; (14) hip
fracture or femoral fracture; (15) other fractures; (16)
Alzheimer’s disease, dementia or senility; (17) benign
tumour and (18) other conditions.
▸ Number of medical symptoms present for at least the past
6 months, from the following list: (1) pain in the
back, knees, hips or any other joint; (2) heart trouble
or angina, chest pain during exercise; (3) breathless-
ness, difﬁculty breathing; (4) persistent cough; (5)
swollen legs; (6) sleeping problems; (7) falling down;
(8). fear of falling down; (9) dizziness, faints or black-
outs; (10) stomach or intestine problems, including
constipation, ‘air’ (ﬂatulence) or diarrhoea; (11)
incontinence or involuntary loss of urine; (12)
fatigue and (13) other symptoms.
▸ Number of conditions for which the respondent takes drugs
at least once a week, from the following list: (1) drugs
for high blood cholesterol; (2) drugs for high blood
pressure; (3) drugs for coronary or cerebrovascular
diseases; (4) drugs for other heart diseases; (5) drugs
for asthma; (6) drugs for diabetes; (7) drugs for joint
pain or for joint inﬂammation; (8) drugs for other
pain (eg, headache, back pain, etc); (9) drugs for
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sleep problems; (10) drugs for anxiety or depression;
(11) drugs for osteoporosis, hormonal; (12) drugs for
osteoporosis, other than hormonal; (13) drugs for
stomach burns; (14) drugs for chronic bronchitis and
(15) other drugs.
▸ Number of contacts with a medical doctor in the past
12 months (excluding dentist visits and hospital stays, but
including emergency room or outpatient clinic visits).
▸ Admitted to hospital in the past 12 months (yes or no;
includes stays in medical, surgical, psychiatric or in
any other specialised wards for at least one night).
Functional domain:
▸ Number of limitations with basic activities of daily living
(BADL, expected to last at least 3 months), from the
following list: (1) bathing or showering; (2) dressing,
including putting on shoes and socks; (3) using the
toilet, including getting up or down; (4) eating, such as
cutting up your food and (5) continence (reported as
incontinence or involuntary loss of urine for at least the
past 6 months). This BADL index is based on the one
by Katz el al,61 but does not include functional transfers
because they are included in the frailty deﬁnition.
▸ Number of limitations with instrumental activities of daily
living (IADL, expected to last at least 3 months), from
the following list: (1) making telephone calls; (2)
shopping for groceries; (3) preparing a hot meal; (4)
doing work around the house or garden; (5) using a
map to ﬁgure out how to get around in a strange
place; (6) taking medications and (7) managing
money, such as paying bills and keeping track of
expenses. This IADL index is based on the one by
Lawton and Brody.62
▸ Received home care for personal or nursing care in the past
12 months: yes or no.
▸ Received home care for domestic tasks in the past
12 months: yes or no.
Psychological and cognitive domains:
▸ EURO-D depression scale.63
▸ Verbal ﬂuency test score: maximum number of different
animals that the respondent is able to name in 60 s.
▸ Delayed word recall: maximum number of words (out of
a list of 10) that the respondent is able to recall after
an initial recall followed by verbal ﬂuency and numer-
acy tests.
Measures for prospective validation
The release of wave 2 data contains a variable that
informs whether respondents were still alive in wave 3,
deceased between wave 2 and wave 3, or with missing
mortality information (ie, 2-year mortality data).
Disability information (BADL and IADL) was sought for
wave 2 respondents who were also included in wave 4
(ie, 4-year disability data).
Statistical analyses
Univariate descriptives
Individual variable descriptives were given as mean and
SD or proportion (%) as appropriate.
Level of significance
It was set at p<0.01 throughout.
Missing frailty phenotype data
Besides the explicit coding of unobserved walking ability,
missing data for all other items of the phenotype were
treated as missing (ie, not given an explicit code).
Internal validation of the frailty measure
In order to assess whether the criteria composing the
frailty measure aggregated statistically into a syndrome, we
estimated (for each gender) a discrete factor (DFactor)
model using the LatentGOLD (V.5.0) latent class model-
ling package (http://www.statisticalinnovations.com). A
single DFactor with three ordered levels (non-frail, prefrail
and frail) was requested. Each DFactor model included
age as a covariate. This procedure is the same as was previ-
ously done for SHARE-FI.32
The outputs from LatentGOLD (V.5.0) are as follows:
(1) loading of each frailty indicator on the underlying
DFactor and its signiﬁcance level; (2) frailty categories as
per the DFactor model (ie, non-frail, prefrail and frail);
(3) continuous frailty score as per the DFactor model
and (4) full DFactor syntax for scoring new cases given
any frailty measurements. For each gender, the
LatentGOLD outputs were saved in the IBM SPSS
Statistics (V.20.0) format and merged with the SHARE
waves 2 and 4 data sets to allow for cross-sectional and
longitudinal correlations.
Correlations of the frailty categories with SHARE wave 2
variables
The two-tailed Spearman’s rank correlation (r) coefﬁ-
cient was used to correlate the (ordinal) frailty category
variable with continuous and ordinal variables; these
correlations were controlled for age using the SPSS
partial correlations procedure. The χ2 for trend was
used to test the association between the frailty variable
and dichotomous variables; to control for the effects of
age, ordinal regression was used (with the frailty variable
as the dependent variable).
Analysis of missing mortality data
For each gender, comparisons between mortality-
available and mortality-unavailable groups were con-
ducted with the χ2 test (for dichotomous variables) or
the Mann–Whitney U test (for continuous or ordinal
variables).
Prospective validation
Binary logistic regression was conducted to assess
whether the ordinal frailty variable signiﬁcantly pre-
dicted whether or not a participant was deceased by
wave 3. Three models were computed: an unadjusted
model (model 1), a model controlling for age (model
2) and one that also controlled for the number of
chronic diseases and limitations with BADL (model 3).
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The 4-year disability outcome was deﬁned as an increase
of ≥1 BADL or IADL disability between waves 2 and 4.
Comparison of SHARE-FI75+ with SHARE-FI and other
SHARE frailty scales
In order to compare SHARE-FI75+ and SHARE-FI32 in
their ability to predict 2-year mortality and 4-year disabil-
ity, the SHARE-FI frailty categories and continuous score
were computed on the SHARE-FI75+ sample using the
published formulae.32 The comparison of proportions
between SHARE-FI75+ and SHARE-FI categories were
conducted with the two-tailed z test (http://www.
socscistatistics.com/tests/ztest/Default.aspx, last accessed
23 August 2014). In addition, the mortalities associated
with the continuous frailty score of both instruments
were compared using receiver operating characteristic
(ROC) curves (IBM SPSS Statistics, V.20.0). Comparative
mortality analyses were also carried out with the follow-
ing additional SHARE frailty scales:
▸ 70-item SHARE Frailty Index (70-SHARE-FIx): an index
was constructed using 70 measures from the physical
health, behavioural risks, cognitive function and
mental health sections of the SHARE wave 2 survey.
This 70-item index is identical to the one previously
operationalised by Theou et al.34 64
▸ SHARE FRAIL scale (SHARE-FRAIL): this scale was
developed as an easy screening tool by Morley and
colleagues,65 and was also adapted to SHARE by
Theou et al.34 64
▸ SHARE frailty phenotype (unweighted; SHARE-FP): in
SHARE-FI32 and SHARE-FI75+, the cut-offs for the
phenotypic categories (ie, non-frail, prefrail and frail)
are automatically derived from LCA, while the ori-
ginal unweighted Fried’s frailty phenotype (as opera-
tionalised in SHARE by Santos-Eggimann et al66) uses
a rule based on the number of criteria present: ≥3:
frail; 1 or 2: prefrail; 0: non-frail.67
Construction of the SHARE-FI75+ calculator
The SHARE-FI75+ interface was designed using
Microsoft Excel 2010. The DFactor syntax (male and
female models) from LatentGOLD (V.5.0; viewed in
SPSS) was translated into Microsoft Excel formulae to
compute the frailty score and categories (ie, non-frail,
prefrail and frail). The bespoke spreadsheet was then
converted to a HTML/Javascript form (webpage) using
a plug-in converter for Excel (SpreadSheetconverter
V.7.7.6036, Framtidsforum I & M AB, Uppsala Sweden,
2002–2014, http://www.spreadsheetconverter.com). A
single form was constructed rather than a separate one
for each gender, which was the case for SHARE-FI. For
this, an initial question on ‘gender’ is asked to deter-
mine which algorithm to use. Note: the technical formu-
lae are described in the online supplementary technical
appendix.
Ethics approval
We undertook a secondary analysis of data obtained
under the SHARE Data Access Rules (http://share-dev.
mpisoc.mpg.de/data-access-documentation/research-data-
center-data-access.html). All participants gave informed
consent before taking part in the study.
Sources of funding
This paper uses data from SHARE wave 4 release 1.1.1,
as of 28 March 2013, and SHARE wave 2 release 2.6.0, as
of 29 November 2013. The SHARE data collection has
been primarily funded by the European Commission
through the ﬁfth Framework Programme (project
QLK6-CT-2001-00360 in the thematic programme
Quality of Life), through the sixth Framework
Programme (projects SHARE-I3, RII-CT-2006-062193,
COMPARE, CIT5-CT-2005-028857, and SHARELIFE,
CIT4-CT-2006-028812) and through the seventh
Framework Programme (SHARE-PREP, N° 211909,
SHARE-LEAP, N° 227822 and SHARE M4, N° 261982).
Additional funding from the US National Institute on
Aging (U01 AG09740-13S2, P01 AG005842, P01
AG08291, P30 AG12815, R21 AG025169, Y1-AG-4553-01,
IAG BSR06-11 and OGHA 04-064) and the German
Ministry of Education and Research as well as from
various national sources is gratefully acknowledged (see
http://www.share-project.org for a full list of funding
institutions).
Statement of independence from funders
The SHARE funding organisations had no role in the
study design; in the collection, analysis and interpretation
of data; in the writing of the report; or in the decision to
submit the article for publication. RR-O and CS are inde-
pendent from the SHARE funding organisations.
Data sharing statement
We undertook a secondary analysis of data obtained
under the SHARE Data Access Rules (http://share-dev.
mpisoc.mpg.de/data-access-documentation/research-data-
center-data-access.html). SHARE data can be accessed by
anyone who abides by those rules. No additional data
are available from the authors.
RESULTS
In total, 4001 women and 3057 men aged 75 years or
more were included in the second wave of SHARE. The
mean age (SD) of women was 81.1 (4.9), and that of men
was 80.4 (4.6). Figure 1 shows the participants’ ﬂow chart.
Estimation of the frailty models
Descriptive statistics for the SHARE-FI75+ variables (by
gender) are reported in table 1. The proportion of
missing data for the walking speed test (49.5% in
women and 44.2% in men) was deemed unacceptably
high; this is why the observed ‘respondent status’ was
used as a surrogate low walking speed criterion (the
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proportion of missing information was 12.1% in women
and 12.7% in men). All other frailty variables had a pro-
portion of missing data of <5% (table 1). Complete data
for the estimation of the frailty models were available for
3325 women (83.1%) and 2587 men (84.6%).
Frailty model for women
The DFactor model included 3325 cases. Nineteen para-
meters were estimated, standard R2=0.69, entropy R2=0.51.
All frailty indicators discriminated well (p<0.001) between
the three classes: non-frail (N=1205; 36.2%), prefrail
(N=1539; 46.3%) and frail (N=581; 17.5%). The following
were the loadings on the DFactor:
▸ Fatigue=0.39 (R2=0.15);
▸ Low appetite=0.28 (R2=0.08);
▸ Weakness=0.56 (R2=0.34);
▸ Observed gait=0.48 (R2=0.26);
▸ Frequency of activities=0.65 (R2=0.43).
Figure 1 Participants’ flow chart (SHARE, the Survey of Health, Ageing and Retirement in Europe).
Table 1 Descriptive statistics for the SHARE-FI75+ variables (by gender)
Women (N=4001) Men (N=3057)
N with
measurement
available
Descriptive
statistic
Per cent
missing
N with
measurement
available
Descriptive
statistic
Per cent
missing
Fatigue (%) 3841 49.4 4.0 2971 38.8 2.8
Low appetite (%) 3862 16.4 3.5 2987 11.9 2.3
Weakness (%) 3980 60.7 0.5 3044 38.6 0.4
Respondent status for the walk test
Unaided (%) 3515 70.6 12.1 2668 77.7 12.7
Aided (%) 17.8 11.4
Chair/bedbound (%) 4.3 3.3
Not observed (%) 7.3 7.5
Walking speed, seconds:
mean (SD)
2019 5.0 (3.9) 49.5 1707 4.4 (3.8) 44.2
Low physical activity
More than weekly (%) 3861 47.5 3.5 3006 58.9 1.7
Once weekly (%) 12.9 11.6
1–3 monthly (%) 6.9 6.5
Hardly ever/never (%) 32.8 23
SHARE-FI, the Frailty Instrument for Primary Care of the Survey of Health, Ageing and Retirement in Europe
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Figure 2 (from the output of LatentGOLD V.5.0)
shows the conditional probabilities (given class member-
ship) for the frailty model in women.
Frailty model for men
The DFactor model included 2587 cases. Nineteen para-
meters were estimated, standard R2=0.68, entropy R2=0.50.
All frailty indicators discriminated well (p<0.001) between
the three classes: non-frail (N=1213; 46.9%), prefrail
(N=1058; 40.9%) and frail (N=316; 12.2%). The following
were the loadings on the DFactor:
▸ Fatigue=0.45 (R2=0.20);
▸ Low appetite=0.32 (R2=0.12);
▸ Weakness=0.62 (R2=0.38);
▸ Observed gait=0.43 (R2=0.22);
▸ Frequency of activities=0.60 (R2=0.36).
Figure 3 shows the conditional probabilities (given
class membership) for the frailty model in men.
Cross-sectional correlations
These are reported in table 2. Our results support that
all age-adjusted cross-sectional correlations were statistic-
ally signiﬁcant. For both women and men, results were
compatible with a biopsychosocial gradient, in the
expected direction, across the frailty categories.
Prediction of mortality
Wave 3 mortality data were available for 2402 women
(72.2% of wave 2 participants with frailty information)
and 1907 men (73.1%). Tables 3 (women) and 4 (men)
report the differences between mortality-available and
mortality-unavailable subgroups. Wave 2 women with no
wave 3 mortality data were signiﬁcantly older and more
frail than those with mortality data (table 3). In men
(table 4), the differences were less marked but still com-
patible with no mortality data being associated with
older age, unobserved gait status and less likelihood of
being able to walk without help (table 4).
As reported in table 2, the 2-year mortality rates in
women were 2.4% for the non-frail category, 5.3% for
the prefrail category and 13.4% for the frail category. In
men, the 2-year mortality rates were 3.9% for the
non-frail category, 9.2% for the prefrail category and
26.3% for the frail category. Model 3 results are compat-
ible with these mortality associations being independent
of baseline age, number of chronic diseases and number
of BADL limitations.
Prediction of disability
Wave 4 disability data were available for 1537 women
(46.2% of the wave 2 sample with frailty information)
and 1114 men (43.1%). Table 2 results are compatible
with a gradient of increasing disability (as also seen in
wave 2) across frailty categories. Results also suggest that
the proportion of at least one more disability between
waves 2 and 4 increased across frailty categories, for both
BADL and IADL, independently of age.
Figure 2 Frailty model for women (LatentGOLD V.5.0 output). The line joined by crosses represents the non-frail category; the
line joined by squares represents the prefrail category; and the line joined by circles represents the frail category. The Y axis
represents the posterior probability for each frailty variable in each frailty category.
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Comparison of SHARE-FI75+ with SHARE-FI and other
SHARE frailty scales
Results in table 2 suggest that the 2-year mortality pre-
diction by SHARE-FI75+ was not inferior to that of
SHARE-FI, judging by the non-signiﬁcant z statistics. The
ROC curves representing the mortality associated with
the continuous scores of SHARE-FI, SHARE-FI75+,
70-SHARE-FIx, SHARE-FRAIL and SHARE-FP are com-
pared in ﬁgures 4 (women) and 5 (men).
Results in table 2 suggest that the 4-year disability pre-
diction was stronger with SHARE-FI75+ for prefrail
women only (for both BADL and IADL); otherwise, no
statistically signiﬁcant differences were seen between
SHARE-FI75+ and SHARE-FI.
Frailty calculator
The Excel and HTML versions of the SHARE-FI75+ cal-
culator are supplied as online supplementary ﬁles. The
syntax for the calculator is detailed in the online supple-
mentary technical appendix.
DISCUSSION
This study created and validated a new phenotypic frailty
assessment tool intended for the 75+ and based on a
large European population-based sample. SHARE-FI75+
could be administered quickly and easily by general prac-
titioners, nurses, pharmacists, home health providers,
social workers and other healthcare workers, in order to
help indicate and prioritise the need for GCA and design
of tailored interventions.18 SHARE-FI75+ is a fully non-
commercial, open access tool intended to facilitate the
identiﬁcation of frailty in community and primary care
settings and promote the equity of access to specialised
geriatric services.
The internal validation of SHARE-FI75+ using LCA
suggested that all its items signiﬁcantly aggregated into
an underlying (unobserved) variable with three ordered
categories (ie, non-frail, prefrail and frail), in keeping
with the phenotype theory.26 For both women and men,
the cross-sectional correlates of SHARE-FI75+ were com-
patible with a biopsychosocial gradient, in the expected
direction, across the frailty categories. SHARE-FI75+ pre-
dicted mortality independently of baseline age,
comorbidity and BADL disability; SHARE-FI75+ was also
positively associated with disability gain at 4 years, inde-
pendently of age. These validation results are in keeping
with the theory that chronological age, comorbidity, dis-
ability and frailty are distinct clinical entities that are
causally related.28
For the development of SHARE-FI75+, we included
one variable for each item of the frailty phenotype and
four subvariables for the ‘walking’ item. Mortality com-
parison with a 70-item frailty index suggested that an
increase in the number of items in the frailty deﬁnition
did not signiﬁcantly improve the prediction of the test.
Figure 3 Frailty model for men (LatentGOLD V.5.0 output). The line joined by crosses represents the non-frail category; the line
joined by squares represents the prefrail category; and the line joined by circles represents the frail category. The Y axis
represents the posterior probability for each frailty variable in each frailty category.
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Table 2 Frailty categories by gender: cross-sectional correlates (wave 2) and prediction of mortality (wave 3) and disability (wave 4)
Women (N=3325) Men (N=2587)
Non-frail
(N=1205)
(36.2%)
Prefrail
(N=1539)
(46.3%)
Frail (N=581)
(17.5%) p Value
Age-adjusted
p value
Non-frail
(N=1213)
(46.9%)
Prefrail
(N=1058)
(40.9%)
Frail (N=316)
(12.2%) p Value
Age-adjusted
p value
Frailty phenotype: DFactor model
Fatigue: yes (cp) 0.27 0.55 0.80 – <0.001* 0.18 0.50 0.81 – <0.001*
Low appetite: yes (cp) 0.06 0.16 0.36 – <0.001* 0.03 0.13 0.38 – <0.001*
Weakness: yes (cp) 0.24 0.75 0.96 – <0.001* 0.09 0.54 0.94 – <0.001*
Observed walking without help (cp) 0.97 0.77 0.21 – <0.001* 0.96 0.79 0.25 – <0.001*
Observed walking with help (cp) 0.01 0.14 0.53 – <0.001* 0.01 0.11 0.44 – <0.001*
Observed in wheelchair/bedbound (cp) <0.01 0.01 0.14 – <0.001* <0.01 0.01 0.19 – <0.001*
Gait not observed (cp) 0.02 0.09 0.12 – <0.001* 0.03 0.10 0.12 – <0.001*
Low activity: hardly ever, or never (cp) 0.03 0.34 0.83 – <0.001* 0.03 0.29 0.75 – <0.001*
Sociodemographic
Age: mean (SD) 79.6 (3.5) 81.7 (4.4) 84.2 (5.4) <0.001† – 79.7 (3.5) 81.4 (4.3) 83.7 (5.4) <0.001† –
No more than primary education (%) 43.6 59.5 70.5 <0.001‡ <0.001§ 36.9 47.4 59.2 <0.001‡ <0.001§
Physical
Poor self-rated health (%) 3.4 21.3 52.5 <0.001‡ <0.001§ 3.8 21.4 55.4 <0.001‡ <0.001§
Number of chronic diseases: mean (SD) 1.9 (1.4) 2.7 (1.7) 3.1 (1.8) <0.001† <0.001¶ 1.6 (1.3) 2.4 (1.6) 2.8 (1.6) <0.001† <0.001¶
Number of symptoms: mean (SD) 1.6 (1.6) 3.3 (2.3) 4.4 (2.5) <0.001† <0.001¶ 1.2 (1.3) 2.6 (2.0) 3.8 (2.2) <0.001† <0.001¶
Number of conditions for which takes
drugs (SD)
1.7 (1.3) 2.7 (1.7) 3.3 (1.9) <0.001† <0.001¶ 1.5 (1.3) 2.3 (1.6) 3.0 (1.8) <0.001† <0.001¶
Number of contacts with doctor in past year:
mean (SD)
6.0 (6.9) 9.7 (10.3) 11.9 (13.7) <0.001† <0.001¶ 6.1 (7.4) 9.4 (10.3) 14.5 (18.1) <0.001† <0.001¶
Admitted to hospital in past year (%) 12.4 23.7 32.4 <0.001‡ <0.001§ 13.9 24.6 35.8 <0.001‡ <0.001§
Functional
Number of limitations with BADL: mean (SD) 0.1 (0.3) 0.5 (0.9) 1.8 (1.5) <0.001† <0.001¶ 0.1 (0.3) 0.4 (0.8) 1.7 (1.5) <0.001† <0.001¶
Number of limitations with IADL: mean (SD) 0.2 (0.5) 1.0 (1.4) 3.2 (2.2) <0.001† <0.001¶ 0.1 (0.5) 0.8 (1.3) 3.1 (2.3) <0.001† <0.001¶
Received home care: personal/nursing (%) 3.8 9.5 28.3 <0.001‡ <0.001§ 3.4 7.5 23.4 <0.001‡ <0.001§
Received home care: domestic tasks (%) 7.6 21.7 34.3 <0.001‡ <0.001§ 4.8 11.1 26.6 <0.001‡ <0.001§
Psychological and cognitive
EURO-D score (minimum: 0;
maximum: 12) (SD)
1.9 (1.7) 3.6 (2.4) 5.5 (2.8) <0.001† <0.001¶ 1.4 (1.6) 2.8 (2.1) 5.2 (2.7) <0.001† <0.001¶
Verbal fluency test score: mean (SD) 16.8 (7.0) 14.1 (7.7) 10.6 (5.7) <0.001† <0.001¶ 17.0 (6.6) 14.9 (6.4) 10.6 (5.6) <0.001† <0.001¶
Delayed word recall score: mean (SD) 2.9 (1.9) 2.1 (1.8) 1.4 (1.6) <0.001† <0.001¶ 2.6 (1.8) 2.1 (1.7) 1.3 (1.4) <0.001† <0.001¶
Mortality at wave 3: SHARE-FI75+
N from wave 2 928 1092 382 – – 922 755 230 – –
Per cent dead 2.4 5.3 13.4 <0.001‡ <0.001§ 3.9 9.2 26.3 <0.001‡ <0.001§
Model 1: unadjusted OR for mortality (95% CI) 1.0 2.3 (1.5 to 3.5) 6.3 (4.1 to 9.8) – – 1.0 2.5 (1.7 to 3.6) 8.8 (6.0 to 13.0) – –
Model 2: age-adjusted OR for mortality
(95% CI)
1.0 1.9 (1.2 to 2.9) 4.1 (2.6 to 6.5) – – 1.0 2.2 (1.6 to 3.2) 6.9 (4.6 to 10.3) – –
Model 3 1.0 1.7 (1.1–2.7) 2.2 (1.2–3.8) – – 1.0 1.9 (1.3–2.8) 4.2 (2.6–6.8) – –
Mortality at Wave 3: SHARE-FI
N from Wave 2 657 1254 374 – – 1141 622 212 – –
% dead 1.9 4.3 9.7 <0.001‡ <0.001§ 4.0 6.7 25.1 <0.001‡ <0.001§
Model 1: unadjusted OR for mortality (95% CI) 1.0 2.4 (1.4 to 4.1) 5.6 (3.2 to 9.9) – – 1.0 1.7 (1.2 to 2.5) 8.1 (5.6 to 11.8) – –
Model 2: age-adjusted OR for mortality
(95% CI)
1.0 2.0 (1.2 to 3.5) 3.9 (2.2 to 7.0) – – 1.0 1.6 (1.1 to 2.3) 6.6 (4.5 to 9.8) – –
Model 3 1.0 2.0 (1.1–3.5) 3.0 (1.6–5.7) – – 1.0 1.5 (1.0–2.2) 5.6 (3.6–8.7) – –
Continued
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Table 2 Continued
Women (N=3325) Men (N=2587)
Non-frail
(N=1205)
(36.2%)
Prefrail
(N=1539)
(46.3%)
Frail (N=581)
(17.5%) p Value
Age-adjusted
p value
Non-frail
(N=1213)
(46.9%)
Prefrail
(N=1058)
(40.9%)
Frail (N=316)
(12.2%) p Value
Age-adjusted
p value
Disability at wave 4: SHARE-FI75+
N from wave 2 684 694 159 – – 621 427 66 – –
Number of limitations with BADL: mean (SD) 0.4 (0.8) 1.1 (1.3) 2.2 (1.7) <0.001† <0.001¶ 0.4 (0.9) 0.9 (1.3) 1.6 (1.6) <0.001† <0.001¶
Increase in BADL disability from wave 2: at
least 1 point (%)
18.3 39.7 49.1 <0.001‡ <0.001§ 17.7 33.7 38.5 <0.001‡ <0.001§
Number of limitations with IADL: mean (SD) 0.7 (1.4) 1.9 (2.2) 3.7 (2.5) <0.001† <0.001¶ 0.7 (1.6) 1.5 (2.2) 2.7 (2.7) <0.001† <0.001¶
Increase in IADL disability from wave 2: at
least 1 point (%)
28.5 48.5 57.9 <0.001‡ <0.001§ 22.2 39.8 39.4 <0.001‡ <0.001§
Disability at wave 4: SHARE-FI
N from wave 2 510 836 204 – – 793 361 68 – –
Number of limitations with BADL: mean (SD) 0.3 (0.7) 0.8 (1.2) 1.6 (1.5) <0.001† <0.001¶ 0.4 (0.9) 0.8 (1.3) 1.2 (1.5) <0.001† <0.001¶
Increase in BADL disability from wave 2: at
least 1 point (%)
17.8 30.9 44.1 <0.001‡ <0.001§ 18.2 32.7 35.3 <0.001‡ <0.001§
Number of limitations with IADL: mean (SD) 0.6 (1.3) 1.4 (1.9) 2.9 (2.2) <0.001† <0.001¶ 0.7 (1.6) 1.3 (2.1) 2.5 (2.4) <0.001† <0.001¶
Increase in IADL disability from wave 2: at
least 1 point (%)
24.7 41.0 52.5 <0.001‡ <0.001§ 23.7 34.1 47.1 <0.001‡ <0.001§
Two-tailed z test for comparison of group proportions (SHARE-FI75+ vs SHARE-FI)
2-year mortality z 0.67 1.13 1.59 – – −0.12 1.70 0.29 – –
p 0.503 0.258 0.112 – – 0.904 0.091 0.772 – –
4-year disability: at least 1 BADL increase z 0.22 3.60 0.95 – – −0.24 0.30 0.38 – –
p 0.826 <0.001 0.342 – – 0.810 0.764 0.704 – –
4-year disability: at least 1
IADL increase
z 1.47 2.94 1.03 – – −0.66 1.65 −0.90 – –
p 0.142 0.003 0.303 – – 0.509 0.099 0.368 – –
Significant p values (<0.01) are indicated in bold.
Model 3: adjusted by age, number of chronic diseases and number of limitations with BADL.
*Wald statistic.
†Two-tailed Spearman’s r test.
‡χ2 for trend.
§Ordinal regression.
¶Partial correlation.
BADL, basic activities of daily living; cp, conditional probability (from the DFactor model profile output); IADLs, instrumental activities of daily living; SHARE-FI, the Frailty Instrument for Primary
Care of the Survey of Health, Ageing and Retirement in Europe.
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On the other hand, one could have added more subvari-
ables for the other frailty phenotype variables in order
to improve the prediction, but this was not attempted in
our study. However, with regard to the variables included
in a frailty index, it has been suggested that they can be
coded either as dichotomous or ordinal, with a negli-
gible impact on the performance of the index in pre-
dicting mortality.68
The prevalences of frailty as per SHARE-FI75+
(women: 36% non-frail, 46% prefrail, 18% frail; men:
47% non-frail, 41% prefrail, 12% frail) are consistent
with the epidemiological literature; in a previous system-
atic review based on 21 cohorts involving 61 500 partici-
pants, the prevalence of frailty was shown to increase
with age and it was 15.7% in those aged 80–84.3
Consistently, epidemiological studies have shown higher
prevalence of frailty (and prefrailty) in women than in
men.3 Conversely, the mortality associated with frailty is
known to be higher in men than in women,69 70 and
this was also the case with SHARE-FI75+ (women: 2%
non-frail, 5% prefrail, 13% frail; men: 4% non-frail, 9%
prefrail, 26% frail).
SHARE-FI75+ might be more feasible than
SHARE-FI32 for implementation in primary care prac-
tice, because handgrip strength (a component of
SHARE-FI) is not typically assessed in primary care and
can add a few minutes to an assessment.36 In contrast, a
busy primary care practitioner will be able to score the
observed gait component of SHARE-FI75+ as soon as
the patient enters through the door, which mirrors a
very natural practice in geriatric assessment.71 72
Furthermore, by including the ‘unobserved’ category in
the gait scoring scheme, SHARE-FI75+ may allow for the
‘tele-assessment’ of frailty (eg, provisional frailty scoring
during telephone consultations). The potential practical
advantages of SHARE-FI75+ over SHARE-FI are not
offset by an inferior risk prediction; indeed,
SHARE-FI75+ had a similar ability to predict 2-year
Table 3 Comparison of baseline characteristics between wave 2 participants with and without mortality data available
(women)
Mortality data
available (N=2402)
Mortality data not
available (N=923)
Significance of the
difference (p)
Frailty variables
Fatigue: yes (%) 48.3 52.0 0.038*
Low appetite: yes (%) 16.7 15.7 0.477*
Weakness: yes (%) 59.3 64.4 0.003*
Observed walking without help (%) 73.3 63.4 <0.001*
Observed walking with help (%) 16.4 21.5 <0.001*
Observed in wheelchair/bedbound (%) 4.2 4.6 0.622*
Gait not observed (%) 6.1 10.5 <0.001*
Low activity: hardly ever, or never (%) 31.5 36.1 0.006*
Frailty categories
Non-frail (%) 38.6 30.0 <0.001*
Prefrail (%) 45.5 48.4 0.124*
Frail (%) 15.9 21.6 <0.001*
Sociodemographic
Age: mean (SD) 80.9 (4.9) 81.5 (5.1) 0.001†
No more than primary education (%) 55.5 56.4 0.735*
Physical
Poor self-rated health (%) 21.1 22.5 0.324*
Number of chronic diseases: mean (SD) 2.5 (1.7) 2.4 (1.7) 0.052†
Number of symptoms: mean (SD) 3.0 (2.4) 2.7 (2.3) 0.011†
Number of contacts with doctor in past year: mean (SD) 9.0 (10.8) 9.1 (11.1) 0.777†
Admitted to hospital in past year (%) 79.3 77.6 0.267*
Functional
Number of limitations with BADL: mean (SD) 0.7 (1.4) 0.7 (1.4) 0.685†
Number of limitations with IADL: mean (SD) 1.2 (1.9) 1.3 (1.9) 0.020†
Received home care: personal/nursing (%) 10.6 11.4 0.497*
Received home care: domestic tasks (%) 17.3 19.6 0.112*
Psychological and cognitive
EURO-D score (minimum: 0; maximum: 12) (SD) 3.2 (2.6) 3.3 (2.6) 0.426†
Verbal fluency test score: mean (SD) 15.0 (7.6) 13.4 (6.5) <0.001†
Delayed word recall score: mean (SD) 2.4 (1.9) 2.2 (1.9) 0.015†
Significant p values (<0.01) are indicated in bold.
*χ2 test.
†Mann–Whitney U test.
BADL, basic activities of daily living; IADL, instrumental activities of daily living.
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mortality and 4-year disability, and even a greater ability
to predict 4-year disability in prefrail women. An add-
itional advantage of SHARE-FI75+ is that three add-
itional European countries are represented in its
validation: Czechia, Poland and Ireland (these countries
were not included in the development of SHARE-FI32).
From the comparative analyses for incident mortality
presented in ﬁgures 4 and 5, one could conclude that
all these tools have very similar performances, in
keeping with the increasingly recognised principle that
rather than being mutually exclusive, different frailty
deﬁnition approaches are complementary and suitable
for different purposes or scenarios.25
Another potential advantage of the SHARE-FI75+ cal-
culator is that it generates age-adjusted results, while the
previous SHARE-FI calculator does not. Thus, the
SHARE-FI75+ is more in keeping with frailty being an
age-independent marker of risk,73 closer to the concept
of biological (as opposed to chronological) age.74 In
addition, an age-adjusted method for frailty screening
may be more sensitive in younger ages and more speciﬁc
in older ages, beneﬁting the purpose of population
screening.75 The continuous, age-adjusted SHARE-FI75+
score values range from 0 to 1, making it a much more
intuitive score than the age-unadjusted one given by
SHARE-FI (−4 to 6).32
A general limitation of SHARE-FI75+ (which also
applied to SHARE-FI) is that, despite being inspired on
the frailty phenotype theory by Fried et al,26 some of the
SHARE items that compose the measure have depar-
tures from Fried’s theoretical framework, namely as
regards ‘weight loss’ (replaced by low appetite), and
‘weakness’ and ‘slowness’ (measured by functional lim-
itations). Thus, compared with the original frailty
phenotype, SHARE-FI75+ may capture people at a more
advanced stage of the disablement process. Nevertheless,
for the validation of SHARE-FI75+, the functional limita-
tions questions composing the measure were not
included in the disability outcomes; this suggests that
SHARE-FI75+ still captures a predisability state, in
Table 4 Comparison of baseline characteristics between wave 2 participants with and without mortality data available (men)
Mortality data
available (N=1907)
Mortality data not
available (N=680)
Significance of the
difference (p)
Frailty variables
Fatigue: yes (%) 38.0 41.1 0.135*
Low appetite: yes (%) 11.4 13.4 0.133*
Weakness: yes (%) 38.0 40.3 0.254*
Observed walking without help (%) 79.1 74.1 0.006*
Observed walking with help (%) 11.0 12.4 0.328*
Observed in wheelchair/bedbound (%) 3.3 3.4 0.939*
Gait not observed (%) 6.6 10.1 0.002*
Low activity: hardly ever, or never (%) 22.2 25.2 0.094*
Frailty categories
Non-frail (%) 48.3 42.8 0.013*
Prefrail (%) 39.6 44.6 0.024*
Frail (%) 12.1 12.6 0.689*
Sociodemographic
Age: mean (SD) 80.2 (4.5) 80.8 (4.7) 0.003†
No more than primary education (%) 42.2 47.2 0.105*
Physical
Poor self-rated health (%) 17.1 20.2 0.053*
Number of chronic diseases: mean (SD) 2.1 (1.6) 2.1 (1.6) 0.832†
Number of symptoms: mean (SD) 2.1 (2.0) 2.1 (2.0) 0.692†
Number of contacts with doctor in past year: mean (SD) 8.3 (9.9) 8.6 (12.2) 0.295†
Admitted to hospital in past year (%) 79.8 75.7 0.015*
Functional
Number of limitations with BADL: mean (SD) 0.5 (1.2) 0.5 (1.3) 0.033†
Number of limitations with IADL: mean (SD) 0.8 (1.7) 0.9 (1.7) 0.046†
Received home care: personal/nursing (%) 7.4 6.6 0.446*
Received home care: domestic tasks (%) 8.8 10.0 0.340*
Psychological and cognitive
EURO-D score (minimum: 0; maximum: 12) (SD) 2.3 (2.3) 2.6 (2.4) 0.040†
Verbal fluency test score: mean (SD) 15.8 (7.0) 15.1 (6.4) 0.020†
Delayed word recall score: mean (SD) 2.3 (1.8) 2.2 (1.8) 0.613†
Significant p values (<0.01) are indicated in bold.
*χ2 test.
†Mann–Whitney U test.
BADL, basic activities of daily living; IADL, instrumental activities of daily living.
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keeping with the frailty phenotype theory.28 SHARE-FI
was also modelled as a vulnerability state prior to the
onset of more severe activity limitation.69
Another limitation of this study is that, owing to the
high proportion of missing data for the walking speed
test in SHARE (50% in women and 44% in men), this
variable could not reliably be used for the construction
of SHARE-FI75+. Instead, the observed respondent
status (which had lower proportions of missing data,
12% in women and 13% in men) was used as a surro-
gate walking speed criterion. Nevertheless, it is known
that performance-based assessments in surveys have
more variable missingness, which suggests that their
implementation in clinical practice may be less feas-
ible.34 The fact that missing mortality data were asso-
ciated with being older and more frail suggests that in
reality, the frailty-associated mortality rates may be
higher than the ones estimated by this study. Other
researchers have shown that death and incapacity are
likely to be important sources of non-response in the
SHARE data.76
A potential limitation our study is that we developed
the SHARE-FI75+ algorithm using the whole sample,
and we did not check the differences of the algorithm
for each country. This is because the sample sizes for
each individual country, once stratiﬁed by gender, are
relatively small for those analyses. In that light, a previ-
ous study with SHARE-FI (which focused on the larger
population aged ≥50 years) showed that the relation-
ships between the construct of frailty and indicators,
although broadly constant, do vary across some coun-
tries; furthermore, there was evidence of differing levels
of frailty for the middle-aged and older populations
across European countries.33
SHARE-FI75+ should be seen as a frailty assessment tool
rather than a frailty screening tool. In fact, with the WHO
screening criteria in mind, the 2013 draft report for the
UK National Screening Committee concluded that at
present there is insufﬁcient evidence to support the
implementation of systematic screening in old age to
prevent hospitalisation and/or early death; however, the
report also highlighted areas for further research,
including the identiﬁcation of measurement tools
(including frailty assessment tools), which are the best
predictors of adverse outcomes in community-dwelling
older people.19
For policymakers, SHARE-FI75+ may represent an easy
to implement tool which focuses on one of the fastest
growing sectors of the population,5 including the biggest
users of health and social care.76 An age-independent
risk assessment may not only promote equity of access to
specialist CGA services, but also help avoid age
Figure 4 Receiver operating characteristic (ROC) curves
comparing the mortality prediction by the Frailty Instrument for
Primary Care of the Survey of Health, Ageing and Retirement
in Europe (SHARE-FI)75+, SHARE-FI, 70-SHARE-FIx,
SHARE-FRAIL and SHARE-FP continuous scores (women).
Areas under the curve (AUC; 95% CI) were: SHARE-FI75+:
0.67 (0.62 to 0.72), p<0.001; SHARE-FI: 0.66 (0.62 to 0.71),
p<0.001; 70-SHARE-FIx: 0.65 (0.61 to 0.70), p<0.001;
SHARE-FRAIL: 0.63 (0.58 to 0.68), p<0.001; SHARE-FP:
0.65 (0.61 to 0.70), p<0.001.
Figure 5 Receiver operating characteristic (ROC) curves
comparing the mortality prediction by the Frailty Instrument for
Primary Care of the Survey of Health, Ageing and Retirement
in Europe (SHARE-FI)75+, SHARE-FI, 70-SHARE-FIx,
SHARE-FRAIL and SHARE-FP continuous scores (men).
Areas under the curve (AUC; 95% CI) were: SHARE-FI75+:
0.71 (0.67 to 0.75), p<0.001; SHARE-FI: 0.71 (0.67 to 0.76),
p<0.001; 70-SHARE-FIx: 0.70 (0.66 to 0.74), p<0.001;
SHARE-FRAIL: 0.68 (0.64 to 0.72), p<0.001; SHARE-FP:
0.69 (0.65 to 0.73), p<0.001.
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discrimination in the provision of health and social care
services.17 The identiﬁcation of frailty as a predisability
condition may allow for preventative interventions
against disability77 78 and facilitate a paradigm of perso-
nalised medicine in old age.79
We would suggest that SHARE-FI75+ is not used in
people younger than 75 years, since its validation was
carried out on the SHARE samples aged 75 or more. In
addition, if someone wants to use the SHARE-FI75+ cal-
culator to classify a participant’s frailty level but does not
have all ﬁve variables, SHARE-FI75+ should not be used,
as it may lose clinical accuracy.
Many frailty identiﬁcation tools exist that may be suit-
able for primary care,37–39 80 but at present none can be
identiﬁed as ‘the best’. Although successful experiences
have been reported from clinical trials with some frailty
tools,30 81 the use of other tools (such as the Groningen
Frailty Indicator82) has been shown to be not more
effective than usual care in reducing disability and
preventing further functional decline in community-
dwelling older people. In that regard, the effectiveness
of SHARE-FI75+ will have to be tested in similar research
studies.
Meanwhile, in response to a strong policy drive for
integration of health and social care services, the
National Health Service (NHS) in England has recently
recommended that incentives be developed that encom-
pass the systematic screening for frailty in people above
the age of 75 in primary care and the creation of regis-
ters of frail older people.48 In its recent draft guidance,
NICE recommends that local authorities and health and
social care providers should use routine appointments
and contacts to identify people at risk of frailty, give
them advice on how to reduce the risks and refer
people to specialist services when necessary.21 While
these innovative, quality improvement-driven pro-
grammes are still at an early developmental stage, they
will allow for the real-life piloting of new frailty assess-
ment tools (such as SHARE-FI75+), and their future
evaluation will provide a valuable complement to the evi-
dence emerging from research studies.
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